Phase I Dose Escalation Study of BAY94-9343 Given by Intravenous Infusion Every 3 Weeks in Japanese Subjects With Advanced Malignancies

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 14, 2015

Primary Completion Date

April 28, 2017

Study Completion Date

July 4, 2017

Conditions

Neoplasms

Interventions

DRUG

BAY94-9343

Cohort 1: 4.5 mg/kg of BAY 94-9343 at Q3W dose regimen. Cohort 2: 6.5 mg/kg of BAY 94-9343 at Q3W dose regimen.

Trial Locations (2)

National Cancer Center Hospital East, Kashiwa

National Cancer Center Hospital, Tyuo